Two Philly Pharmacies Booted from DEA Over Record-Keeping Fails
Published Date: 4/16/2025
Notice
Summary
Empire Pharmacy and Skyline Pharmacy in Philadelphia lost their DEA registrations because they didn’t keep proper records of controlled substances, which could risk public safety. Their registrations were suspended immediately, and since they didn’t ask for a hearing, the suspension and revocation are now final. This means they can’t legally handle controlled drugs anymore, affecting their business and customers starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Pending Renewals and New Registrations Denied
The DEA not only revoked the pharmacies' registrations but also denied any pending applications by Empire Pharmacy Inc. and Skyline Pharmacy Inc. to renew, modify, or obtain additional DEA registrations in Pennsylvania. The denial is effective May 16, 2025, blocking these businesses from legally regaining or expanding controlled-substance registration in the State.
Two Philly Pharmacies Can’t Dispense Controlled Drugs
The DEA revoked the registrations for Empire Pharmacy Inc. (DEA No. FE8167733) and Skyline Pharmacy Inc. (DEA No. FS0903840), so they may no longer legally handle or dispense controlled substances. The revocations are final and the Order is effective May 16, 2025, meaning customers who relied on these pharmacies for controlled medications will need to get those prescriptions elsewhere.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Previous / Next Documents
Previous: 2025-06424 — David Israel, M.D.; Decision and Order
Dr. David Israel from Bronx, NY, lost his DEA license because he wrote prescriptions for controlled drugs in ways that broke the law. This means he can’t legally handle these drugs anymore, and his registration expired in late 2023. If you’re a patient or pharmacy, this change is immediate and affects how controlled substances are managed.
Next: 2025-06426 — Moustafa M. Aboshady, M.D.; Decision and Order
Dr. Moustafa M. Aboshady’s application to register with the DEA in Salt Lake City was denied because he’s barred from federal health programs like Medicare and Medicaid. He asked for a hearing but missed key deadlines to respond properly, so the DEA moved forward without his full defense. This means he can’t legally handle controlled substances, affecting his medical practice and income starting early 2024.